At the forefront of therapies for rare and orphan diseasesTM
about us| programs| science & technology | patient advocacy | clinical studies | investors | collaborations | news & events
Amicus Therapeutics is a biopharmaceutical company developing next-generation treatments for a broad range of human genetic diseases, with a focus on improving therapies for lysosomal storage diseases.
02/26/2015 Amicus Therapeutics to Present at Cowen and Company 35th Annual Health Care Conference
02/25/2015 Amicus Therapeutics to Announce Full-Year 2014 Financial Results on March 3, 2015
02/10/2015 Amicus Therapeutics Announces Additional Positive Phase 3 Fabry Data on Patient Reported Outcomes at WORLDSymposium(TM) 2015
Amicus Therapeutics CEO: Driving science to a cure
John Crowley, Amicus Therapeutics chairman and CEO, discusses its Fabry pill development and next generation therapy for Pompe disease, with CNBC's Jim Cramer.

Click Here to Read the Article

Copyright © 2015 Amicus Therapeutics, Inc. All rights reserved.   Terms of Use | Privacy Policy